ICICI Prudential Mutual Fund has reported the sale of 3,36,110 equity shares of Thyrocare Technologies Ltd. This transaction, executed on August 12, 2026, resulted in a net decrease of 2.06% in the fund’s paid-up capital holding of the company. The sale reduces the fund’s stake from a previously disclosed 5.33% as of October 27, 2025, indicating a strategic shift in its investment portfolio for this specific asset.
ICICI Prudential MF Reduces Thyrocare Holding
ICICI Prudential Mutual Fund has announced the sale of a substantial block of shares in Thyrocare Technologies Ltd. The transaction involved the disposal of 3,36,110 equity shares on August 12, 2026. This strategic sale represents a significant reduction in the fund’s investment in the company.
Impact on Shareholding
Following the sale, the overall shareholding of ICICI Prudential Mutual Fund in Thyrocare Technologies has decreased by more than 2% of the company’s paid-up capital, compared to the disclosure made on October 27, 2025. At that time, the fund’s holding stood at 5.33%. The net sale, as detailed in the disclosure, amounts to 2.06% of the paid-up capital from the period between October 27, 2025, and October 24, 2025.
The disclosed holdings and transactions are from an investment perspective, with no objective to gain controlling interest in the target company. The disclosures are made in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Key Transaction Details
As per the format for disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011:
- Target Company: Thyrocare Technologies Ltd.
- Seller: ICICI Prudential Mutual Fund
- Stock Exchange: BSE Limited, National Stock Exchange of India Limited
- Holding before sale: 84,71,670 shares (5.33% of total shares/voting capital)
- Shares sold (Net): 32,62,621 shares (2.06% of total shares/voting capital)
- Holding after sale: 52,09,049 shares (3.27% of total shares/voting capital)
- Mode of Sale: Open Market
- Date of Sale Period: October 25, 2025, to August 12, 2026
The equity share capital of Thyrocare Technologies Ltd. before the said disposal was ₹1,58,98,33,410, comprising 15,89,83,341 shares of face value ₹10/- each. After the disposal, the equity share capital is ₹1,59,16,53,150, comprising 15,91,65,315 shares of face value ₹10/- each. The total diluted share/voting capital after the sale is ₹1,59,63,02,520, consisting of 15,96,30,252 shares of face value ₹10/- each.
It is noted that the number of shares of the Company had increased due to a bonus issuance in the ratio of 2:1 in November 2025, which has been adjusted for disclosure purposes.
Source: BSE
